Evercore ISI resumed coverage of Travere Therapeutics (TVTX) with an Outperform rating and $30 price target after “a brief pause” prompted by the sale of the bile acid product portfolio to Mirum Pharmaceuticals (MIRM). Final data from the PROTECT study that the firm expects by early Q4 will be a first look at eGFR in IgAN and is both “critical to secure full approval” and a “key catalyst,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TVTX:
- Insider Trading: Mirum (NASDAQ:MIRM) Stock Sees Huge Insider Buy
- Travere Therapeutics completes sale of bile acid product portfolio
- Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
- Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023